目的探讨帕金森病患者外周血浆及红细胞中α-突触核蛋白(α-syn)寡聚体含量对帕金森病诊断以及与病程、疾病严重程度的相关性。方法2013年3月至2014年12月,采集30例帕金森病患者(患者组)及30例健康体检者(对照组)血液,采用酶联免疫吸附测定法检测血浆及红细胞中α-syn寡聚体含量。结果对照组血浆及红细胞中α-syn寡聚体含量低于患者组(t>2.346, P<0.05);两组红细胞中α-syn寡聚体含量高于血浆中含量(t>2.242, P<0.05);患者组血浆及红细胞中α-syn寡聚体含量与病程、Hoehn-Yahr分期、帕金森病综合评分量表第3部分评分、帕金森病非运动症状问卷评分、简易精神状态检查评分均无相关性(P>0.05)。结论帕金森病患者外周血浆及红细胞中α-syn寡聚体含量有助于帕金森病诊断,但不具有监测疾病进展价值。
ObjectiveTo investigate the level of alpha-synuclein (α-syn) oligomers in peripheral blood plasma and red blood cells (RBC) in patients with Parkinson's disease (PD), and the value of it for diagnosis and evaluation of PD. MethodsFrom March, 2013 to December, 2014, peripheral blood samples were collected from 30 PD patients and 30 healthy coutrols, and the level of α-syn oligomers in plasma and RBC was detected with enzyme linked immunosorbent assay. ResultsThe level of α-syn oligomers was less in both plasma and RBC in the controls than in the patients (t>2.346, P<0.05), and was more in RBC than in plasma in both the controls and the patients (t>2.242, P<0.05). The level of α-syn oligomers of patients did not correlate with their course, Hoehn-Yahr Stage, the scores of Unified Parkinson Disease Rating Scale Part 3, Non-Motor Symptom Quest and Mini-Mental State Examinatlon, both in plasma and RBC (P>0.05). ConclusionThe level of α-syn oligomers in peripheral RBC and plasma may be helpful for diagnosis of PD, but less for the evaluation of the illness.
[1] Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease [J]. Mov Disord, 2008, 23(8): 1065-1075.
[2] George S, Rey NY, Reichenbach N, et al. α-synuclein: the long distance runner [J]. Brain Pathol, 2013, 23(3): 350-357.
[3] El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease [J]. FASEB J, 2006, 20(3): 419-425.
[4] 李昕,杨巍巍,于顺,等. 一种检测帕金森患者血浆促进α-突触核蛋白寡聚体形成能力的方法[J]. 首都医科大学学报, 2013, 34(6): 830-834.
[5] Foulds PG, Mitchell JD, Parker A, et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease [J]. FASEB J, 2011, 25(12): 4127-4137.
[6] 尹娜,陈予东,李昕,等. 帕金森病患者血浆增强α-突触核蛋白寡聚体形成[J]. 首都医科大学学报, 2013, 34(6): 840-843.
[7] Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood [J]. Neurodegener Dis, 2008, 5(2): 55-59.
[8] Claton DJ, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders [J]. J Neurosci Res, 1999, 58(1): 120-129.
[9] 李雁,殷娟娟,李昕. α-突触核蛋白寡聚体对多巴胺能神经细胞线粒体膜电位的影响[J]. 中国现代神经疾病杂志, 2008, 8(1): 26-32.
[10] Ono K, Yamada M. Alpha-synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy [J]. Rinsho Byori, 2014, 62(3): 241-245.
[11] Landis GN, Tower J. Superoxide dismutase evolution and life span regulation [J]. Mech Ageing Dev, 2005, 126(3): 365-379.
[12] Zhang W, Wang TG, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease [J]. FASEB J, 2005, 19(6): 533-542.
[13] Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death [J]. J Neurosci, 2006, 26(1): 41-50.
[14] Mollenhauer B. Quantification of α-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease? [J]. Parkinsonism Relat Disord, 2014, 20(1): S76-S79.
[15] Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging [J]. Magn Reson Imaging, 2005, 23(1): 1-25.
[16] Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias [J]. Mov Disord, 2011, 26(8): 1428-1435.
